CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for e-Therapeutics plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

e-Therapeutics plc
Floor 4
4 Kingdom Street, Paddington Central
Phone: +44 2045518888p:+44 2045518888 LONDON, W2 6BD  United Kingdom Ticker: ETXETX
Business Summary
e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
1/31/20231/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
7374 Computer processing and data preparation and processing services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board Trevor M.Jones 79 3/1/2021 10/29/2015
Chief Executive Officer, Executive Director AliMortazavi 52 3/1/2021 2/10/2020
Interim Chief Financial Officer, Non-Executive Director MichaelBretherton 12/31/2021 2/11/2020
4 additional Officers and Directors records available in full report.

Business Names
Business Name
e-Therapeutics plc
ETX
ETXPF
InRotis Technologies Limited
Searchbolt Limited

General Information
Number of Employees: 38 (As of 1/31/2023)
Outstanding Shares: 584,335,487 (As of 1/31/2024)
Stock Exchange: LON
Fax Number: +44 1993880207


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024